Scholarlink

Background <p>Gastroesophageal junction (GEJ) adenocarcinoma is aggressive with poor prognosis. Perioperative chemotherapy has become standard, but the optimal regimen remains uncertain. DOS has shown activity in gastric cancer but has not been prospectively assessed in GEJ adenocarcinoma. This study represents the first prospective trial of DOS as neoadjuvant chemotherapy in patients with resectable GEJ adenocarcinoma.</p> Methods <p>This single-arm, single-center phase I/II trial (UMIN000022210) enrolled patients with cT3–4aN0–3M0 GEJ adenocarcinoma. The phase I part established the recommended docetaxel dose (60&#xa0;mg/m<sup>2</sup>); phase II evaluated efficacy and safety. The primary endpoint was R0 resection rate; and secondary endpoints included pathological response, adverse events, and 3-year survival.</p> Results <p>Forty-three patients were enrolled; 37 received DOS at the recommended dose. Of these, 83.8% completed all planned cycles. Grade ≥ 3 neutropenia occurred in 81.1%, and febrile neutropenia in 18.9%. The R0 resection rate was 94.6% (35/37; 95% CI, 81.8–99.3). Major postoperative complications occurred in 11.4%, with no operative mortality. Major pathological response was achieved in 40.5% of patients, including a pathological complete response rate of 5.4%. At 3&#xa0;years, overall survival and relapse-free survival were 84.9% and 64.5%, respectively. Patients downstaged to ypStage 0 or IA had significantly better relapse-free survival than others.</p> Conclusions <p>Neoadjuvant DOS chemotherapy showed high R0 resection rates, acceptable toxicity, and favorable survival in resectable GEJ adenocarcinoma, supporting its potential as a treatment option. These findings provide important evidence from East Asia, where S-1-based regimens remain widely used, and complement Western data on perioperative FLOT therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma

  • 期刊论文

  • 发表日期：

    2026年2月21日

查看全文
  • Koshi Kumagai,
  • Kei Hosoda,
  • Chikatoshi Katada,
  • Kenji Ishido,
  • Akinori Watanabe,
  • Takuya Wada,
  • Masahiro Niihara,
  • Tadashi Higuchi,
  • Mikiko Sakuraya,
  • Marie Washio,
  • Motohiro Chuman,
  • Hiroki Harada,
  • Shohei Fujita,
  • Kota Okuno,
  • Keishi Yamashita,
  • Yusuke Kumamoto,
  • Takeshi Naitoh,
  • Chika Kusano,
  • Naoki Hiki

摘要

Background

Gastroesophageal junction (GEJ) adenocarcinoma is aggressive with poor prognosis. Perioperative chemotherapy has become standard, but the optimal regimen remains uncertain. DOS has shown activity in gastric cancer but has not been prospectively assessed in GEJ adenocarcinoma. This study represents the first prospective trial of DOS as neoadjuvant chemotherapy in patients with resectable GEJ adenocarcinoma.

Methods

This single-arm, single-center phase I/II trial (UMIN000022210) enrolled patients with cT3–4aN0–3M0 GEJ adenocarcinoma. The phase I part established the recommended docetaxel dose (60 mg/m2); phase II evaluated efficacy and safety. The primary endpoint was R0 resection rate; and secondary endpoints included pathological response, adverse events, and 3-year survival.

Results

Forty-three patients were enrolled; 37 received DOS at the recommended dose. Of these, 83.8% completed all planned cycles. Grade ≥ 3 neutropenia occurred in 81.1%, and febrile neutropenia in 18.9%. The R0 resection rate was 94.6% (35/37; 95% CI, 81.8–99.3). Major postoperative complications occurred in 11.4%, with no operative mortality. Major pathological response was achieved in 40.5% of patients, including a pathological complete response rate of 5.4%. At 3 years, overall survival and relapse-free survival were 84.9% and 64.5%, respectively. Patients downstaged to ypStage 0 or IA had significantly better relapse-free survival than others.

Conclusions

Neoadjuvant DOS chemotherapy showed high R0 resection rates, acceptable toxicity, and favorable survival in resectable GEJ adenocarcinoma, supporting its potential as a treatment option. These findings provide important evidence from East Asia, where S-1-based regimens remain widely used, and complement Western data on perioperative FLOT therapy.